1. In this randomized controlled trial, rates of ventilator-associated pneumonia (VAP) were lower in ventilated patients using amikacin as compared to a placebo. 2. This difference was maintained over a 28-day follow-up period in the amikacin group. Evidence Rating Level: 1 (Excellent) Study Rundown: VAP emerges 48 hours or more post-mechanical ventilation via an endotracheal